SPL-16

N/A

Report date: 2022/11/14 14:30:10

NME

Base Information

Drug NameSPL-16

Drug Alias NameSPL-16

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators

TargetsCystic fibrosis transmembrane conductance regulator

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSplisense Ltd

China Registration ClassN/A

Active CompaniesSplisense Ltd

Inactive CompaniesN/A

Active IndicationsCystic Fibrosis

Inactive IndicationsN/A

ATC CodeN/A